Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Elettroliti sierici e nefropatia indotta da contrasto in pazienti con ictus ischemico acuto sottoposti a trattamento endovascolare

L'Impatto dei Livelli Sierici di Elettroliti sul Rischio di Nefropatia Indotta da Mezzo di Contrasto in Pazienti con Ictus Ischemico Acuto Sottoposti a Terapia Endovascolare

This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT).

Contrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated.

In this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups.

The primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.

Panoramica dello studio

Descrizione dettagliata

This retrospective cohort study is designed to evaluate the association between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients undergoing endovascular therapy (EVT) for acute ischemic stroke.

Endovascular treatment has become a standard of care for acute ischemic stroke; however, the use of iodinated contrast media carries a risk of nephrotoxicity. Contrast-induced acute kidney injury remains a clinically significant complication and is associated with prolonged hospitalization, increased healthcare costs, and higher mortality rates. Although several well-established risk factors for CI-AKI have been identified, including baseline renal dysfunction, diabetes mellitus, and contrast volume, the role of serum electrolyte imbalances has not been clearly defined.

Electrolyte disturbances may influence renal perfusion, tubular function, and systemic hemodynamics, potentially contributing to the pathophysiology of CI-AKI. Therefore, identifying electrolyte-related risk factors may help improve risk stratification and guide preventive strategies in high-risk populations.

In this study, patients who underwent EVT between 2018 and 2026 will be included. Prospectively collected clinical data will be analyzed retrospectively. Patients will be divided into two groups based on the development of CI-AKI, defined according to changes in serum creatinine levels following contrast exposure.

Comparative analyses will be performed between patients with and without CI-AKI to identify potential predictors. Multivariate regression analysis may be used to determine independent risk factors associated with CI-AKI development.

The findings of this study are expected to provide clinically relevant insights into the role of electrolyte balance in the development of CI-AKI and may contribute to improved peri-procedural risk assessment and patient management strategies in acute ischemic stroke populations undergoing endovascular therapy.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

4760

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Outside of the US
      • Diyarbakır, Outside of the US, Turchia (Türkiye), 21070
        • Fatma Acil

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 100 anni (Adulto, Adulto più anziano)

Accetta volontari sani

N/A

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

This study includes adult patients (≥18 years) with acute ischemic stroke who underwent endovascular therapy at a tertiary referral center between 2018 and 2026. Patients with sufficient clinical and laboratory data, including pre- and post-procedural serum creatinine measurements, will be eligible for inclusion.

The cohort reflects a real-world population of patients undergoing EVT, encompassing a wide range of demographic and clinical characteristics, including common vascular comorbidities. Patients will be stratified according to the development of contrast-induced acute kidney injury (CI-AKI) for comparative analyses.

Descrizione

Inclusion Criteria:

  • Adults aged 18 years or older
  • Patients diagnosed with acute ischemic stroke
  • Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026
  • Patients with a baseline NIHSS score of 6 or higher
  • Patients who received iodinated contrast medium during the endovascular procedure
  • Patients managed under general anesthesia
  • Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury

Exclusion Criteria:

  • Age younger than 18 years
  • Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy
  • APACHE score greater than 25 at the time of the procedure
  • Known allergy or hypersensitivity to iodinated contrast media
  • Exposure to iodinated contrast media within the previous 2 weeks
  • Use of nephrotoxic medications within the previous 2 weeks
  • History of myocardial infarction or previous stroke
  • Use of vasopressor/inotropic agents such as dopamine at the time of the procedure
  • Systemic steroid use at the time of the procedure
  • Incomplete medical records or missing laboratory data required for evaluation of CI-AKI

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: RETROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
CI-AKI Group

Patients who developed contrast-induced acute kidney injury (CI-AKI) following endovascular therapy for acute ischemic stroke, defined by an increase in serum creatinine levels according to established diagnostic criteria after contrast exposure. These patients were identified based on post-procedural renal function changes and included in the analysis to evaluate clinical, laboratory, and procedural factors associated with CI-AKI development.

No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development.

Non-CI-AKI Group

Patients who underwent endovascular therapy for acute ischemic stroke but did not develop contrast-induced acute kidney injury based on post-procedural serum creatinine measurements.

No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of contrast-induced acute kidney injury (CI-AKI)
Lasso di tempo: Within 48-72 hours after contrast exposure

CI-AKI will be identified based on post-procedural serum creatinine changes after contrast exposure according to established diagnostic criteria.

Within 48-72 hours after contrast exposure

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
90-day mortality
Lasso di tempo: Within 90 days after endovascular therapy

All-cause mortality occurring within 90 days after endovascular therapy in patients with and without contrast-induced acute kidney injury (CI-AKI).

Within 90 days after endovascular therapy
Dialysis dependency in patients with CI-AKI
Lasso di tempo: Within 90 days after endovascular therapy

Requirement for renal replacement therapy (hemodialysis) within 90 days after endovascular therapy in patients who developed contrast-induced acute kidney injury (CI-AKI)

Within 90 days after endovascular therapy
Change in serum creatinine
Lasso di tempo: Baseline to 48-72 hours after endovascular therapy

Change in serum creatinine levels from baseline to post-procedural measurements following contrast exposure.

Baseline to 48-72 hours after endovascular therapy
Association between serum electrolyte levels and CI-AKI
Lasso di tempo: Baseline (pre-procedural measurements)

Evaluation of the relationship between baseline serum electrolyte levels (sodium, potassium, chloride, calcium, magnesium, phosphate) and the development of contrast-induced acute kidney injury.

Baseline (pre-procedural measurements)
Length of hospital stay
Lasso di tempo: Within 90 days after endovascular therapy

Total duration of hospitalization in days, compared between patients with and without CI-AKI.

Within 90 days after endovascular therapy
Inflammatory markers and CI-AKI relationship
Lasso di tempo: Baseline (pre-procedural measurements)

Association between inflammatory markers (e.g., C-reactive protein, procalcitonin) and the development of CI-AKI.

Baseline (pre-procedural measurements)
Change in estimated glomerular filtration rate (eGFR)
Lasso di tempo: Baseline to 48-72 hours after endovascular therapy

Change in estimated glomerular filtration rate (eGFR) from baseline to post-procedural measurements following contrast exposure

Baseline to 48-72 hours after endovascular therapy

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

23 aprile 2026

Completamento primario (Effettivo)

10 novembre 2026

Completamento dello studio (Effettivo)

11 novembre 2026

Date di iscrizione allo studio

Primo inviato

2 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 aprile 2026

Primo Inserito (Effettivo)

22 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi